Moderna’s stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.

"The S&P 500 is a different animal than in prior cycles," Bank of America's Savita Subramanian said in a note Friday.

The first few earnings reports from S&P 500 firms have already started to trickle in. But the fourth-quarter earnings ...

“However, rates should stay at higher levels relative to the pre-Covid era,” he says ... says he believes the stock market will ultimately post a positive return in 2024 as investors ...

Intel revenues dropped from $79 billion in 2021 to $54 billion in 2023 as CPU sales declined due to the cooling off of the PC market post-Covid-19 and ... an individual stock, consider the High ...

American Airlines is seeing stock growth in 2025 due to strategic focus, fleet modernization, and debt management. See why we ...

On January 3, the Indian stock market fell significantly. Meanwhile, in China, the COVID-like HMPV virus is wreaking havoc, ...

He reiterated his in line rating on the stock and his $60 price target. Separately, Moderna said it has filed for approval of its next-generation COVID-19 vaccine and has filed for approval of its ...